New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177)

Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis and radionuclide therapy of prostate cancer. This study reports conversion of a previously reported Ga-68-imaging agent, [Ga-68]Ga-P16-093, to a Lu-177 radionuclide therapeutic agent. Substitution of the HBED-CC metal chelating group with DOTA(GA)(2) led to P17-087 (4) and P17-088 (7). Both agents showed excellent PSMA binding affinity (IC50 = 10-30 nM) comparable to that of recently FDA-approved [Lu-177]Lu-PSMA-617 (Pluvicto). Biodistribution studies in PSMA expressing tumor bearing mice showed that [Lu-177]Lu-4 exhibited very high tumor uptake and a fast blood clearance similar to those of [Lu-177]Lu-PSMA-617. Conversely, [Lu-177]Lu-7, containing an albumin binder, extended its blood half-life and exhibited significantly higher uptake and longer tumor residence time than [Lu-177]Lu-4 and [Lu-177]Lu-PSMA-617. The switch from chelator HBED-CC to DOTA(GA)(2) and the switch from the imaging isotope gallium-68 to the therapeutic isotope lutetium-177 have successfully transformed a PSMA-targeting agent from diagnosis to promising radionuclide therapeutic agents.

Automated summary

This study successfully transformed a PSMA-targeting imaging agent into promising radionuclide therapeutic agents using Lu-177 isotope. Both newly developed agents showed excellent PSMA binding affinity and exhibited good tumor uptake and blood clearance in a mouse model. One of the agents also demonstrated an extended blood half-life and longer tumor residence time.